APO Research
Talk to an analyst

APO RESEARCH · REPORT

Myotonic Dystrophy Drug

Myotonic dystrophy is a type of muscular dystrophy, a group of long-term genetic disorders that impair muscle function. Symptoms include gradually worsening muscle loss and weakness. Muscles often contract and are unable to relax. Other symptoms may include cataracts, intellectual disability and heart conduction problems. In men, there may be early balding and an inability to have children.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Myotonic dystrophy is a type of muscular dystrophy, a group of long-term genetic disorders that impair muscle function. Symptoms include gradually worsening muscle loss and weakness. Muscles often contract and are unable to relax. Other symptoms may include cataracts, intellectual disability and heart conduction problems. In men, there may be early balding and an inability to have children.

Myotonic dystrophy affects more than 1 in 8,000 people worldwide. While myotonic dystrophy can occur at any age, onset is typically in the 20s and 30s. It is the most common form of muscular dystrophy that begins in adulthood.

Drugs that have been used to treat myotonia include sodium channel blockers such as procainamide, phenytoin and mexiletine, tricyclic antidepressant drugs such as clomipramine or imipramine, benzodiazepines, calcium antagonists, taurine and prednisone.

Selected research

Industry Growth & Trends

Global Myotonic Dystrophy Drug Industry Growth and Trends Forecast to 2032

28 December 202595 pages

Choose your research edition.

Industry ResearchMyotonic Dystrophy Drug Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Myotonic Dystrophy Drug Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Myotonic Dystrophy Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Myotonic Dystrophy Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Myotonic Dystrophy Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Myotonic dystrophy is a type of muscular dystrophy, a group of long-term genetic disorders that impair muscle function. Symptoms include gradually worsening muscle loss and weakness. Muscles often contract and are unable to relax. Other symptoms may include cataracts, intellectual disability and heart conduction problems. In men, there may be early balding and an inability to have children.

Myotonic dystrophy affects more than 1 in 8,000 people worldwide. While myotonic dystrophy can occur at any age, onset is typically in the 20s and 30s. It is the most common form of muscular dystrophy that begins in adulthood.

Drugs that have been used to treat myotonia include sodium channel blockers such as procainamide, phenytoin and mexiletine, tricyclic antidepressant drugs such as clomipramine or imipramine, benzodiazepines, calcium antagonists, taurine and prednisone.

Read the full market overview

The classification of Myotonic Dystrophy Drug includes Sodium Channel Blocker, Tricyclic Antidepressant and Other, and the sale proportion of Sodium Channel Blocker in 2019 is about 50%. Myotonic Dystrophy Drug is widely sold through Hospital Pharmacy, Retail Pharmacy, etc. The most proportion of Myotonic Dystrophy Drug sold through for Hospital Pharmacy, and the proportion in 2019 is nearly 45%. North America is the largest consumption place, with a consumption market share over 45% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 28%. Lupin, Teva, ANI Pharmaceuticals, Mylan, Novartis, etc. are the leaders of the industry, with totally about 60% market shares.

Report Scope

This report provides a structured, data-driven view of the global Myotonic Dystrophy Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Myotonic Dystrophy Drug market size, estimates, and forecasts are presented in terms of sales volume (K Unit) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Myotonic Dystrophy Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Myotonic Dystrophy Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Myotonic Dystrophy Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Myotonic Dystrophy Drug Market by Company

Lupin

Teva

ANI Pharmaceuticals

Mylan

Novartis

Sun Pharma

Mallinckrodt

Myotonic Dystrophy Drug Segment by Type

Sodium Channel Blocker

Tricyclic Antidepressant

Other

Myotonic Dystrophy Drug Segment by Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Other

Myotonic Dystrophy Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Myotonic Dystrophy Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Myotonic Dystrophy Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Myotonic Dystrophy Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Myotonic Dystrophy Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Myotonic Dystrophy Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Sodium Channel Blocker Table 2. Major Company of Tricyclic Antidepressant Table 3. Major Company of Other Table 4. Global Myotonic Dystrophy Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Myotonic Dystrophy Drug Sales by Type (2021-2026) & (K Unit) Table 6. Global Myotonic Dystrophy Drug Sales Market Share in Volume by Type (2021-2026) Table 7. Global Myotonic Dystrophy Drug Sales by Type (2021-2026) & (US$ Million) Table 8. Global Myotonic Dystrophy Drug Sales Market Share in Value by Type (2021-2026) Table 9. Global Myotonic Dystrophy Drug Price by Type (2021-2026) & (USD$/Unit) Table 10. Global Myotonic Dystrophy Drug Sales by Type (2027-2032) & (K Unit) Table 11. Global Myotonic Dystrophy Drug Sales Market Share in Volume by Type (2027-2032) Table 12. Global Myotonic Dystrophy Drug Sales by Type (2027-2032) & (US$ Million) Table 13. Global Myotonic Dystrophy Drug Sales Market Share in Value by Type (2027-2032) Table 14. Global Myotonic Dystrophy Drug Price by Type (2027-2032) & (USD$/Unit) Table 15. North America Myotonic Dystrophy Drug Sales by Type (2021-2026) & (K Unit) Table 16. North America Myotonic Dystrophy Drug Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Myotonic Dystrophy Drug Sales by Type (2021-2026) & (K Unit) Table 18. Europe Myotonic Dystrophy Drug Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Myotonic Dystrophy Drug Sales by Type (2021-2026) & (K Unit) Table 20. Asia-Pacific Myotonic Dystrophy Drug Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Myotonic Dystrophy Drug Sales by Type (2021-2026) & (K Unit) Table 22. Latin America Myotonic Dystrophy Drug Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Myotonic Dystrophy Drug Sales by Type (2021-2026) & (K Unit) Table 24. Middle East and Africa Myotonic Dystrophy Drug Sales by Type (2021-2026) & (US$ Million) Table 25. Myotonic Dystrophy Drug Industry Trends Table 26. Myotonic Dystrophy Drug Industry Drivers Table 27. Myotonic Dystrophy Drug Industry Opportunities and Challenges Table 28. Myotonic Dystrophy Drug Industry Restraints Table 29. Global Myotonic Dystrophy Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Myotonic Dystrophy Drug Revenue Market Share by Company (2021-2026) Table 31. Global Myotonic Dystrophy Drug Sales by Company (2021-2026) & (K Unit) Table 32. Global Myotonic Dystrophy Drug Sales Share by Company (2021-2026) Table 33. Global Myotonic Dystrophy Drug Market Price by Company (2021-2026) & (USD$/Unit) Table 34. Global Myotonic Dystrophy Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Myotonic Dystrophy Drug Major Company Production Sites and Headquarters Table 36. Global Myotonic Dystrophy Drug Company, Product Type & Application Table 37. Global Myotonic Dystrophy Drug Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Myotonic Dystrophy Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Myotonic Dystrophy Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Myotonic Dystrophy Drug Sales by Region (2021-2026) & (K Unit) Table 42. Global Myotonic Dystrophy Drug Sales Market Share in Volume by Region (2021-2026) Table 43. Global Myotonic Dystrophy Drug Sales by Region (2021-2026) & (US$ Million) Table 44. Global Myotonic Dystrophy Drug Sales Market Share in Value by Region (2021-2026) Table 45. Global Myotonic Dystrophy Drug Sales (K Unit), Value (US$ Million), Price (USD$/Unit) and Gross Margin (2021-2026) Table 46. Global Myotonic Dystrophy Drug Sales by Region (2027-2032) & (K Unit) Table 47. Global Myotonic Dystrophy Drug Sales Market Share in Volume by Region (2027-2032) Table 48. Global Myotonic Dystrophy Drug Sales by Region (2027-2032) & (US$ Million) Table 49. Global Myotonic Dystrophy Drug Sales Market Share in Value by Region (2027-2032) Table 50. Global Myotonic Dystrophy Drug Sales (K Unit), Value (US$ Million), Price (USD$/Unit) and Gross Margin (2027-2032) Table 51. Global Myotonic Dystrophy Drug Sales by Distribution Channel (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Myotonic Dystrophy Drug Sales by Distribution Channel (2021-2026) & (K Unit) Table 53. Global Myotonic Dystrophy Drug Sales Market Share in Volume by Distribution Channel (2021-2026) Table 54. Global Myotonic Dystrophy Drug Sales by Distribution Channel (2021-2026) & (US$ Million) Table 55. Global Myotonic Dystrophy Drug Sales Market Share in Value by Distribution Channel (2021-2026) Table 56. Global Myotonic Dystrophy Drug Price by Distribution Channel (2021-2026) & (USD$/Unit) Table 57. Global Myotonic Dystrophy Drug Sales by Distribution Channel (2027-2032) & (K Unit) Table 58. Global Myotonic Dystrophy Drug Sales Market Share in Volume by Distribution Channel (2027-2032) Table 59. Global Myotonic Dystrophy Drug Sales by Distribution Channel (2027-2032) & (US$ Million) Table 60. Global Myotonic Dystrophy Drug Sales Market Share in Value by Distribution Channel (2027-2032) Table 61. Global Myotonic Dystrophy Drug Price by Distribution Channel (2027-2032) & (USD$/Unit) Table 62. North America Myotonic Dystrophy Drug Sales by Distribution Channel (2021-2026) & (K Unit) Table 63. North America Myotonic Dystrophy Drug Sales by Distribution Channel (2021-2026) & (US$ Million) Table 64. Europe Myotonic Dystrophy Drug Sales by Distribution Channel (2021-2026) & (K Unit) Table 65. Europe Myotonic Dystrophy Drug Sales by Distribution Channel (2021-2026) & (US$ Million) Table 66. Asia-Pacific Myotonic Dystrophy Drug Sales by Distribution Channel (2021-2026) & (K Unit) Table 67. Asia-Pacific Myotonic Dystrophy Drug Sales by Distribution Channel (2021-2026) & (US$ Million) Table 68. Latin America Myotonic Dystrophy Drug Sales by Distribution Channel (2021-2026) & (K Unit) Table 69. Latin America Myotonic Dystrophy Drug Sales by Distribution Channel (2021-2026) & (US$ Million) Table 70. Middle East and Africa Myotonic Dystrophy Drug Sales by Distribution Channel (2021-2026) & (K Unit) Table 71. Middle East and Africa Myotonic Dystrophy Drug Sales by Distribution Channel (2021-2026) & (US$ Million) Table 72. Lupin Company Information Table 73. Lupin Business Overview Table 74. Lupin Myotonic Dystrophy Drug Sales (K Unit), Revenue (US$ Million), Price (USD$/Unit) and Gross Margin (2021-2026) Table 75. Lupin Myotonic Dystrophy Drug Product Portfolio Table 76. Lupin Recent Development Table 77. Teva Company Information Table 78. Teva Business Overview Table 79. Teva Myotonic Dystrophy Drug Sales (K Unit), Revenue (US$ Million), Price (USD$/Unit) and Gross Margin (2021-2026) Table 80. Teva Myotonic Dystrophy Drug Product Portfolio Table 81. Teva Recent Development Table 82. ANI Pharmaceuticals Company Information Table 83. ANI Pharmaceuticals Business Overview Table 84. ANI Pharmaceuticals Myotonic Dystrophy Drug Sales (K Unit), Revenue (US$ Million), Price (USD$/Unit) and Gross Margin (2021-2026) Table 85. ANI Pharmaceuticals Myotonic Dystrophy Drug Product Portfolio Table 86. ANI Pharmaceuticals Recent Development Table 87. Mylan Company Information Table 88. Mylan Business Overview Table 89. Mylan Myotonic Dystrophy Drug Sales (K Unit), Revenue (US$ Million), Price (USD$/Unit) and Gross Margin (2021-2026) Table 90. Mylan Myotonic Dystrophy Drug Product Portfolio Table 91. Mylan Recent Development Table 92. Novartis Company Information Table 93. Novartis Business Overview Table 94. Novartis Myotonic Dystrophy Drug Sales (K Unit), Revenue (US$ Million), Price (USD$/Unit) and Gross Margin (2021-2026) Table 95. Novartis Myotonic Dystrophy Drug Product Portfolio Table 96. Novartis Recent Development Table 97. Sun Pharma Company Information Table 98. Sun Pharma Business Overview Table 99. Sun Pharma Myotonic Dystrophy Drug Sales (K Unit), Revenue (US$ Million), Price (USD$/Unit) and Gross Margin (2021-2026) Table 100. Sun Pharma Myotonic Dystrophy Drug Product Portfolio Table 101. Sun Pharma Recent Development Table 102. Mallinckrodt Company Information Table 103. Mallinckrodt Business Overview Table 104. Mallinckrodt Myotonic Dystrophy Drug Sales (K Unit), Revenue (US$ Million), Price (USD$/Unit) and Gross Margin (2021-2026) Table 105. Mallinckrodt Myotonic Dystrophy Drug Product Portfolio Table 106. Mallinckrodt Recent Development Table 107. North America Myotonic Dystrophy Drug Market Size Growth Rate (CAGR) by Country (K Unit): 2021 VS 2025 VS 2032 Table 108. North America Myotonic Dystrophy Drug Sales by Country (2021-2026) & (K Unit) Table 109. North America Myotonic Dystrophy Drug Sales Market Share by Country (2021-2026) Table 110. North America Myotonic Dystrophy Drug Sales Forecast by Country (2027-2032) & (K Unit) Table 111. North America Myotonic Dystrophy Drug Sales Market Share Forecast by Country (2027-2032) Table 112. North America Myotonic Dystrophy Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 113. North America Myotonic Dystrophy Drug Market Size by Country (2021-2026) & (US$ Million) Table 114. North America Myotonic Dystrophy Drug Market Share by Country (2021-2026) Table 115. North America Myotonic Dystrophy Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 116. North America Myotonic Dystrophy Drug Market Share Forecast by Country (2027-2032) Table 117. Europe Myotonic Dystrophy Drug Market Size Growth Rate (CAGR) by Country (K Unit): 2021 VS 2025 VS 2032 Table 118. Europe Myotonic Dystrophy Drug Sales by Country (2021-2026) & (K Unit) Table 119. Europe Myotonic Dystrophy Drug Sales Market Share by Country (2021-2026) Table 120. Europe Myotonic Dystrophy Drug Sales Forecast by Country (2027-2032) & (K Unit) Table 121. Europe Myotonic Dystrophy Drug Sales Market Share Forecast by Country (2027-2032) Table 122. Europe Myotonic Dystrophy Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 123. Europe Myotonic Dystrophy Drug Market Size by Country (2021-2026) & (US$ Million) Table 124. Europe Myotonic Dystrophy Drug Market Share by Country (2021-2026) Table 125. Europe Myotonic Dystrophy Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 126. Europe Myotonic Dystrophy Drug Market Share Forecast by Country (2027-2032) Table 127. Asia-Pacific Myotonic Dystrophy Drug Market Size Growth Rate (CAGR) by Country (K Unit): 2021 VS 2025 VS 2032 Table 128. Asia-Pacific Myotonic Dystrophy Drug Sales by Country (2021-2026) & (K Unit) Table 129. Asia-Pacific Myotonic Dystrophy Drug Sales Market Share by Country (2021-2026) Table 130. Asia-Pacific Myotonic Dystrophy Drug Sales Forecast by Country (2027-2032) & (K Unit) Table 131. Asia-Pacific Myotonic Dystrophy Drug Sales Market Share Forecast by Country (2027-2032) Table 132. Asia-Pacific Myotonic Dystrophy Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 133. Asia-Pacific Myotonic Dystrophy Drug Market Size by Country (2021-2026) & (US$ Million) Table 134. Asia-Pacific Myotonic Dystrophy Drug Market Share by Country (2021-2026) Table 135. Asia-Pacific Myotonic Dystrophy Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 136. Asia-Pacific Myotonic Dystrophy Drug Market Share Forecast by Country (2027-2032) Table 137. Latin America Myotonic Dystrophy Drug Market Size Growth Rate (CAGR) by Country (K Unit): 2021 VS 2025 VS 2032 Table 138. Latin America Myotonic Dystrophy Drug Sales by Country (2021-2026) & (K Unit) Table 139. Latin America Myotonic Dystrophy Drug Sales Market Share by Country (2021-2026) Table 140. Latin America Myotonic Dystrophy Drug Sales Forecast by Country (2027-2032) & (K Unit) Table 141. Latin America Myotonic Dystrophy Drug Sales Market Share Forecast by Country (2027-2032) Table 142. Latin America Myotonic Dystrophy Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 143. Latin America Myotonic Dystrophy Drug Market Size by Country (2021-2026) & (US$ Million) Table 144. Latin America Myotonic Dystrophy Drug Market Share by Country (2021-2026) Table 145. Latin America Myotonic Dystrophy Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 146. Latin America Myotonic Dystrophy Drug Market Share Forecast by Country (2027-2032) Table 147. Middle East and Africa Myotonic Dystrophy Drug Market Size Growth Rate (CAGR) by Country (K Unit): 2021 VS 2025 VS 2032 Table 148. Middle East and Africa Myotonic Dystrophy Drug Sales by Country (2021-2026) & (K Unit) Table 149. Middle East and Africa Myotonic Dystrophy Drug Sales Market Share by Country (2021-2026) Table 150. Middle East and Africa Myotonic Dystrophy Drug Sales Forecast by Country (2027-2032) & (K Unit) Table 151. Middle East and Africa Myotonic Dystrophy Drug Sales Market Share Forecast by Country (2027-2032) Table 152. Middle East and Africa Myotonic Dystrophy Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 153. Middle East and Africa Myotonic Dystrophy Drug Market Size by Country (2021-2026) & (US$ Million) Table 154. Middle East and Africa Myotonic Dystrophy Drug Market Share by Country (2021-2026) Table 155. Middle East and Africa Myotonic Dystrophy Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 156. Middle East and Africa Myotonic Dystrophy Drug Market Share Forecast by Country (2027-2032) Table 157. Key Raw Materials Table 158. Raw Materials Key Suppliers Table 159. Myotonic Dystrophy Drug Distributors List Table 160. Myotonic Dystrophy Drug Customers List Table 161. Research Programs/Design for This Report Table 162. Authors List of This Report Table 163. Secondary Sources Table 164. Primary Sources List of Figures Figure 1. Myotonic Dystrophy Drug Image Figure 2. Global Myotonic Dystrophy Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Myotonic Dystrophy Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Myotonic Dystrophy Drug Sales (2021-2032) & (K Unit) Figure 5. Sodium Channel Blocker Image Figure 6. Global Sodium Channel Blocker Sales YoY Growth (2021-2032) & (K Unit) Figure 7. Tricyclic Antidepressant Image Figure 8. Global Tricyclic Antidepressant Sales YoY Growth (2021-2032) & (K Unit) Figure 9. Other Image Figure 10. Global Other Sales YoY Growth (2021-2032) & (K Unit) Figure 11. Global Myotonic Dystrophy Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Myotonic Dystrophy Drug Market Share by Type 2025 VS 2032 Figure 13. North America Myotonic Dystrophy Drug Sales Market Share in Volume by Type in 2025 Figure 14. North America Myotonic Dystrophy Drug Sales Market Share in Value by Type in 2025 Figure 15. Europe Myotonic Dystrophy Drug Sales Market Share in Volume by Type in 2025 Figure 16. Europe Myotonic Dystrophy Drug Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Myotonic Dystrophy Drug Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Myotonic Dystrophy Drug Sales Market Share in Value by Type in 2025 Figure 19. Latin America Myotonic Dystrophy Drug Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Myotonic Dystrophy Drug Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Myotonic Dystrophy Drug Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Myotonic Dystrophy Drug Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Myotonic Dystrophy Drug Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Hospital Pharmacy Image Figure 26. Global Hospital Pharmacy Sales YoY Growth (2021-2032) & (K Unit) Figure 27. Retail Pharmacy Image Figure 28. Global Retail Pharmacy Sales YoY Growth (2021-2032) & (K Unit) Figure 29. Other Image Figure 30. Global Other Sales YoY Growth (2021-2032) & (K Unit) Figure 31. Global Myotonic Dystrophy Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Myotonic Dystrophy Drug Market Share by Application 2025 VS 2032 Figure 33. North America Myotonic Dystrophy Drug Sales Market Share in Volume by Application in 2025 Figure 34. North America Myotonic Dystrophy Drug Sales Market Share in Value by Application in 2025 Figure 35. Europe Myotonic Dystrophy Drug Sales Market Share in Volume by Application in 2025 Figure 36. Europe Myotonic Dystrophy Drug Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Myotonic Dystrophy Drug Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Myotonic Dystrophy Drug Sales Market Share in Value by Application in 2025 Figure 39. Latin America Myotonic Dystrophy Drug Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Myotonic Dystrophy Drug Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Myotonic Dystrophy Drug Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Myotonic Dystrophy Drug Sales Market Share in Value by Application in 2025 Figure 43. North America Myotonic Dystrophy Drug Sales by Country: 2021 VS 2025 VS 2032 (K Unit) Figure 44. North America Myotonic Dystrophy Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Myotonic Dystrophy Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Myotonic Dystrophy Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Myotonic Dystrophy Drug Sales by Country: 2021 VS 2025 VS 2032 (K Unit) Figure 48. Europe Myotonic Dystrophy Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Myotonic Dystrophy Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Myotonic Dystrophy Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Myotonic Dystrophy Drug Sales by Country: 2021 VS 2025 VS 2032 (K Unit) Figure 52. Asia-Pacific Myotonic Dystrophy Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Myotonic Dystrophy Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Myotonic Dystrophy Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Myotonic Dystrophy Drug Sales by Country: 2021 VS 2025 VS 2032 (K Unit) Figure 56. Latin America Myotonic Dystrophy Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Myotonic Dystrophy Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Myotonic Dystrophy Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Myotonic Dystrophy Drug Sales by Country: 2021 VS 2025 VS 2032 (K Unit) Figure 60. Middle East and Africa Myotonic Dystrophy Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Myotonic Dystrophy Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Myotonic Dystrophy Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Myotonic Dystrophy Drug Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Myotonic Dystrophy Drug Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Sodium Channel Blocker
  • Tricyclic Antidepressant
  • Other
Applications
  • Hospital Pharmacy
  • Retail Pharmacy
  • Other
Companies covered
  • Lupin
  • Teva
  • ANI Pharmaceuticals
  • Mylan
  • Novartis
  • Sun Pharma
  • Mallinckrodt

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Myotonic Dystrophy Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Myotonic Dystrophy Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Myotonic Dystrophy Drug Market by Type
  6. 1.3.1 Sodium Channel Blocker
  7. 1.3.2 Tricyclic Antidepressant
  8. 1.3.3 Other
  9. 1.4 Global Myotonic Dystrophy Drug Market Size by Type
  10. 1.4.1 Global Myotonic Dystrophy Drug Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Myotonic Dystrophy Drug Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Myotonic Dystrophy Drug Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Myotonic Dystrophy Drug Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Myotonic Dystrophy Drug Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Myotonic Dystrophy Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Myotonic Dystrophy Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Myotonic Dystrophy Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Myotonic Dystrophy Drug Industry Trends
  2. 2.2 Myotonic Dystrophy Drug Industry Drivers
  3. 2.3 Myotonic Dystrophy Drug Industry Opportunities and Challenges
  4. 2.4 Myotonic Dystrophy Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Myotonic Dystrophy Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Myotonic Dystrophy Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Myotonic Dystrophy Drug Price (2021-2026)
  4. 3.4 Global Myotonic Dystrophy Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Myotonic Dystrophy Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Myotonic Dystrophy Drug Company, Product Type & Application
  7. 3.7 Global Myotonic Dystrophy Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Myotonic Dystrophy Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Myotonic Dystrophy Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Myotonic Dystrophy Drug Tier 1, Tier 2, and Tier 3
4 Myotonic Dystrophy Drug Regional Status and Outlook
  1. 4.1 Global Myotonic Dystrophy Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Myotonic Dystrophy Drug Historic Market Size by Region
  3. 4.2.1 Global Myotonic Dystrophy Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Myotonic Dystrophy Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Myotonic Dystrophy Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Myotonic Dystrophy Drug Forecasted Market Size by Region
  7. 4.3.1 Global Myotonic Dystrophy Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Myotonic Dystrophy Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Myotonic Dystrophy Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Myotonic Dystrophy Drug by Application
  1. 5.1 Myotonic Dystrophy Drug Market by Distribution Channel
  2. 5.1.1 Hospital Pharmacy
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Myotonic Dystrophy Drug Market Size by Distribution Channel
  6. 5.2.1 Global Myotonic Dystrophy Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Myotonic Dystrophy Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Myotonic Dystrophy Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Distribution Channel
  10. 5.3.1 North America Myotonic Dystrophy Drug Sales Breakdown by Distribution Channel (2021-2026)
  11. 5.3.2 Europe Myotonic Dystrophy Drug Sales Breakdown by Distribution Channel (2021-2026)
  12. 5.3.3 Asia-Pacific Myotonic Dystrophy Drug Sales Breakdown by Distribution Channel (2021-2026)
  13. 5.3.4 South America Myotonic Dystrophy Drug Sales Breakdown by Distribution Channel (2021-2026)
  14. 5.3.5 Middle East and Africa Myotonic Dystrophy Drug Sales Breakdown by Distribution Channel (2021-2026)
6 Company Profiles
  1. 6.1 Lupin
  2. 6.1.1 Lupin Company Information
  3. 6.1.2 Lupin Business Overview
  4. 6.1.3 Lupin Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Lupin Myotonic Dystrophy Drug Product Portfolio
  6. 6.1.5 Lupin Recent Developments
  7. 6.2 Teva
  8. 6.2.1 Teva Company Information
  9. 6.2.2 Teva Business Overview
  10. 6.2.3 Teva Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Teva Myotonic Dystrophy Drug Product Portfolio
  12. 6.2.5 Teva Recent Developments
  13. 6.3 ANI Pharmaceuticals
  14. 6.3.1 ANI Pharmaceuticals Company Information
  15. 6.3.2 ANI Pharmaceuticals Business Overview
  16. 6.3.3 ANI Pharmaceuticals Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 ANI Pharmaceuticals Myotonic Dystrophy Drug Product Portfolio
  18. 6.3.5 ANI Pharmaceuticals Recent Developments
  19. 6.4 Mylan
  20. 6.4.1 Mylan Company Information
  21. 6.4.2 Mylan Business Overview
  22. 6.4.3 Mylan Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Mylan Myotonic Dystrophy Drug Product Portfolio
  24. 6.4.5 Mylan Recent Developments
  25. 6.5 Novartis
  26. 6.5.1 Novartis Company Information
  27. 6.5.2 Novartis Business Overview
  28. 6.5.3 Novartis Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Novartis Myotonic Dystrophy Drug Product Portfolio
  30. 6.5.5 Novartis Recent Developments
  31. 6.6 Sun Pharma
  32. 6.6.1 Sun Pharma Company Information
  33. 6.6.2 Sun Pharma Business Overview
  34. 6.6.3 Sun Pharma Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Sun Pharma Myotonic Dystrophy Drug Product Portfolio
  36. 6.6.5 Sun Pharma Recent Developments
  37. 6.7 Mallinckrodt
  38. 6.7.1 Mallinckrodt Company Information
  39. 6.7.2 Mallinckrodt Business Overview
  40. 6.7.3 Mallinckrodt Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Mallinckrodt Myotonic Dystrophy Drug Product Portfolio
  42. 6.7.5 Mallinckrodt Recent Developments
7 North America by Country
  1. 7.1 North America Myotonic Dystrophy Drug Sales by Country
  2. 7.1.1 North America Myotonic Dystrophy Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Myotonic Dystrophy Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Myotonic Dystrophy Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Myotonic Dystrophy Drug Market Size by Country
  6. 7.2.1 North America Myotonic Dystrophy Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Myotonic Dystrophy Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Myotonic Dystrophy Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Myotonic Dystrophy Drug Sales by Country
  2. 8.1.1 Europe Myotonic Dystrophy Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Myotonic Dystrophy Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Myotonic Dystrophy Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Myotonic Dystrophy Drug Market Size by Country
  6. 8.2.1 Europe Myotonic Dystrophy Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Myotonic Dystrophy Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Myotonic Dystrophy Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Myotonic Dystrophy Drug Sales by Country
  2. 9.1.1 Asia-Pacific Myotonic Dystrophy Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Myotonic Dystrophy Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Myotonic Dystrophy Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Myotonic Dystrophy Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Myotonic Dystrophy Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Myotonic Dystrophy Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Myotonic Dystrophy Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Myotonic Dystrophy Drug Sales by Country
  2. 10.1.1 South America Myotonic Dystrophy Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Myotonic Dystrophy Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Myotonic Dystrophy Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Myotonic Dystrophy Drug Market Size by Country
  6. 10.2.1 South America Myotonic Dystrophy Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Myotonic Dystrophy Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Myotonic Dystrophy Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Myotonic Dystrophy Drug Sales by Country
  2. 11.1.1 Middle East and Africa Myotonic Dystrophy Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Myotonic Dystrophy Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Myotonic Dystrophy Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Myotonic Dystrophy Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Myotonic Dystrophy Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Myotonic Dystrophy Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Myotonic Dystrophy Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Myotonic Dystrophy Drug Value Chain Analysis
  2. 12.1.1 Myotonic Dystrophy Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Myotonic Dystrophy Drug Production Mode & Process
  7. 12.2 Myotonic Dystrophy Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Myotonic Dystrophy Drug Distributors
  10. 12.2.3 Myotonic Dystrophy Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst